142 related articles for article (PubMed ID: 17436085)
21. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
23. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
24. [Cigu Xiaozhi pills's influence on lipid peroxidation and TNF-alpha expression in liver tissues of rats with nonalcoholic steatohepatitis].
Ma Y; Zhao J; Yang S; Jia Y
Zhongguo Zhong Yao Za Zhi; 2010 May; 35(10):1292-7. PubMed ID: 20707200
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone for nonalcoholic steatohepatitis.
Dogru T; Ercin CN; Erdem G; Tapan S; Tasci I; Sonmez A
Gastroenterology; 2008 Dec; 135(6):2156. PubMed ID: 19013165
[No Abstract] [Full Text] [Related]
26. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice.
Kawai D; Takaki A; Nakatsuka A; Wada J; Tamaki N; Yasunaka T; Koike K; Tsuzaki R; Matsumoto K; Miyake Y; Shiraha H; Morita M; Makino H; Yamamoto K
Hepatology; 2012 Sep; 56(3):912-21. PubMed ID: 22505328
[TBL] [Abstract][Full Text] [Related]
27. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet.
Romestaing C; Piquet MA; Letexier D; Rey B; Mourier A; Servais S; Belouze M; Rouleau V; Dautresme M; Ollivier I; Favier R; Rigoulet M; Duchamp C; Sibille B
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E110-9. PubMed ID: 17986629
[TBL] [Abstract][Full Text] [Related]
29. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.
Lutchman G; Promrat K; Kleiner DE; Heller T; Ghany MG; Yanovski JA; Liang TJ; Hoofnagle JH
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1048-52. PubMed ID: 16814613
[TBL] [Abstract][Full Text] [Related]
30. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
Ren T; Zhu J; Zhu L; Cheng M
Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
[TBL] [Abstract][Full Text] [Related]
31. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
32. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
[TBL] [Abstract][Full Text] [Related]
33. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
34. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Fujita K; Yoneda M; Wada K; Mawatari H; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Saito S; Iwasaki T; Terauchi Y; Nakajima A
Dig Dis Sci; 2007 Dec; 52(12):3455-64. PubMed ID: 17410441
[TBL] [Abstract][Full Text] [Related]
35. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women.
Berberoglu Z; Gursoy A; Bayraktar N; Yazici AC; Bascil Tutuncu N; Guvener Demirag N
J Clin Endocrinol Metab; 2007 Sep; 92(9):3523-30. PubMed ID: 17595249
[TBL] [Abstract][Full Text] [Related]
37. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
[TBL] [Abstract][Full Text] [Related]
38. Oat β-glucan inhibits lipopolysaccharide-induced nonalcoholic steatohepatitis in mice.
You S; Hu X; Zhao Q; Chen X; Xu C
Food Funct; 2013 Sep; 4(9):1360-8. PubMed ID: 23851679
[TBL] [Abstract][Full Text] [Related]
39. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
